REBECCA MIZRAHI: Open Payments
NPI 1104499409 · OCEANPORT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,592 in 100 payments from 16 companies in 2025. Trend: 2023 $1,513 · 2024 $884 · 2025 $1,592
Food & beverage: $1,592
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 11 | $269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $253 |
| Alkermes, Inc. | 14 | $235 |
| ABBVIE INC. | 18 | $175 |
| Vanda Pharmaceuticals Inc. | 8 | $147 |
| Lundbeck LLC | 11 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Bausch Health US, LLC | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
Products named: Auvelity, CAPLYTA, REXULTI, ARISTADA, VRAYLAR, FANAPT, TRINTELLIX, APLENZIN.
Industry payments across NJ — which companies pay providers there.
